- Home
- TBRG vs CVRX Comparison
TBRG vs CVRX Comparison
Compare TBRG & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- CVRX
- Stock Information
- Founded
- TBRG 1979
- CVRX 2000
- Country
- TBRG United States
- CVRX United States
- Employees
- TBRG N/A
- CVRX N/A
- Industry
- TBRG
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TBRG
- CVRX Health Care
- Exchange
- TBRG NYSE
- CVRX Nasdaq
- Market Cap
- TBRG 401.2M
- CVRX 419.8M
- IPO Year
- TBRG N/A
- CVRX 2021
- Fundamental
- Price
- TBRG $28.11
- CVRX $12.49
- Analyst Decision
- TBRG Buy
- CVRX Strong Buy
- Analyst Count
- TBRG 3
- CVRX 7
- Target Price
- TBRG $23.67
- CVRX $17.83
- AVG Volume (30 Days)
- TBRG 200.3K
- CVRX 221.5K
- Earning Date
- TBRG 03-10-2025
- CVRX 04-29-2025
- Dividend Yield
- TBRG N/A
- CVRX N/A
- EPS Growth
- TBRG N/A
- CVRX N/A
- EPS
- TBRG N/A
- CVRX N/A
- Revenue
- TBRG $342,646,000.00
- CVRX $51,292,000.00
- Revenue This Year
- TBRG $5.97
- CVRX $27.21
- Revenue Next Year
- TBRG $6.94
- CVRX $25.87
- P/E Ratio
- TBRG N/A
- CVRX N/A
- Revenue Growth
- TBRG 1.99
- CVRX 30.53
- 52 Week Low
- TBRG $7.61
- CVRX $6.40
- 52 Week High
- TBRG $32.00
- CVRX $19.24
- Technical
- Relative Strength Index (RSI)
- TBRG 51.50
- CVRX 47.44
- Support Level
- TBRG $27.38
- CVRX $11.80
- Resistance Level
- TBRG $29.78
- CVRX $12.94
- Average True Range (ATR)
- TBRG 1.66
- CVRX 0.58
- MACD
- TBRG -0.13
- CVRX 0.20
- Stochastic Oscillator
- TBRG 35.17
- CVRX 64.73
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.